Clinical Trials Directory

Trials / Sponsors / CRISPR Therapeutics AG

CRISPR Therapeutics AG

Industry · 10 registered clinical trials — 4 currently recruiting.

StatusTrialPhaseStarted
RecruitingA Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
Cardiovascular, Metabolic Disease, Dyslipidemias
Phase 12024-06-21
Enrolling By InvitationA Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
Hematologic Malignancy, Solid Malignancy
—2023-11-22
CompletedA Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma
Phase 1 / Phase 22023-03-13
RecruitingA Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy
Phase 1 / Phase 22023-03-10
RecruitingAn Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in S
Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders
Phase 1 / Phase 22023-01-20
CompletedAn Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects Wi
Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders
Phase 12022-01-24
TerminatedA Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies
T Cell Lymphoma
Phase 12020-07-31
TerminatedA Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (CO
Renal Cell Carcinoma
Phase 12020-06-16
TerminatedA Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Phase 12020-01-22
TerminatedA Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CAR
B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma
Phase 1 / Phase 22019-07-22